Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Neuromyelitis Optica Spectrum Disorders (NMOSDs)
NCT05356858Phase 2Terminated
- Sponsor
- Xuanwu Hospital
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Xuanwu Hospital. Started May 2022; status: terminated.
02
Drugs
zanubrutinib
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05356858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05356858.